Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04592809 · ClinicalTrials.gov registry record · Phase 3
Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
A Phase 3 study of Suicide, Attempted and Suicide Threat, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04592809 is a Phase 3 study of Suicide, Attempted and Suicide Threat that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 50 participants, below the 378-participant average among 36 other Suicide, Attempted trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04592809, a Phase 3 study of Suicide, Attempted and Suicide Threat, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This project aims to examine the signal of efficacy of ketamine, a rapidly acting medication shown to decrease suicidality in adults in as short as hours or days, as opposed to weeks. The study design is a double-blind, randomized, active-control trial of adolescents (ages 13-18 years) with recent suicidal behaviors (suicide attempt or increased suicidal ideation). All participants must be receiving standard of care treatment which may range broadly from both outpatient and inpatient programs which include clinically indicated psychosocial and/or psychopharmacological treatments. Ketamine/midazolam treatment will occur twice weekly during the first two weeks of the study, followed by weekly assessments through week 12.
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
- DRUG Midazolam Hydrochloride
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04592809
The ClinicalTrials.gov registry entry for NCT04592809 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 36 other Suicide, Attempted trials with a reported enrollment target (87% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Suicide, Attempted appearing as the primary indexed condition, and to 2 interventions - of which Ketamine Hydrochloride is the first listed.
NCT04592809 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04592809 about?
NCT04592809 is a clinical study titled "Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents". This project aims to examine the signal of efficacy of ketamine, a rapidly acting medication shown to decrease suicidality in adults in as short as hours or days, as opposed to weeks. The study design is a double-blind, randomized, active-control trial of adolescents (ages 13-18 years) with recent ...
What is the current status of trial NCT04592809?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2022-10-03. Estimated completion is 2025-08-31.
What conditions does trial NCT04592809 study?
This clinical trial studies the following conditions: Suicide, Attempted, Suicide Threat, Suicide and Depression.
What interventions are being tested in trial NCT04592809?
The interventions under investigation include: Ketamine Hydrochloride (DRUG), Midazolam Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04592809?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04592809 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide, Attempted
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine Treatment of Youth Suicide Attempters
RECRUITING · Phase 3
-
Community-Based Cognitive Therapy for Suicide Attempters
COMPLETED · Phase 3
-
Virtual Reality Lethal Means Safety Training
RECRUITING · NA
-
Skills to Enhance Positivity in Suicidal Youth
RECRUITING · NA
-
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
RECRUITING · NA
-
Suicide Intervention for Alaska Native Youth
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.